HTA Quarterly Spring 2024
By AmerisourceBergen
It’s Just…So…Cool – Don’t miss your opportunity for JSC!
Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries
Heard on the street
“Because AstraZeneca has no legitimate claim of entitlement to sell its drugs to the government at any price other than what the government is willing to pay, its due process claim fails as a matter of law.”
U.S. District Judge Colm Connolly wrote in his opinion regarding a lawsuit that challenged the constitutionality of the Inflation Reduction Act (IRA) in a federal court in Delaware, less than 3 weeks after a Texas judge tossed a similar lawsuit by industry lobbying group PhRMA.
Delaware court dismisses AstraZeneca suit challenging IRA
HTA by the numbers
100%
"I think one of the remarkable things about the presentations that I saw today at this conference was that literally 100% of the payers and providers who presented today mentioned AI as a prominent part of their strategy for 2024," said Julie Yoo, general partner at Andreessen Horowitz, while moderating a conference panel discussion on AI.
JPM24: Top trends for payers, providers and health tech companies to watch